ArticleMedComm2025
PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study.
Riqing Huang, Haifeng Li, Shuo Li, Ditian Shu, Rishang Chen, Zhousan Zheng, Tinghua Gao, Meiting Chen, Anqi Hu, Yunjie Huang and 5 more
Abstract read
In one paragraphArticle in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Riqing HuangState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Haifeng LiState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Shuo LiState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Ditian ShuState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Rishang ChenMedical Oncology Department III Central Hospital of Guangdong Nongken Zhanjiang P. R. China.
Zhousan ZhengDepartment of Oncology The First Affiliated Hospital of Sun Yat-sen University Guangzhou P. R. China.
Tinghua GaoDepartment of Oncology The First People's Hospital of Zhaoqing City Zhaoqing P. R. China.
Meiting ChenState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.ORCID https://orcid.org/0000-0002-7195-1300 Anqi HuState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Yunjie HuangState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Qiufan ZhengState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Xin AnState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Cong XueState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Yuchen CaiState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.
Yanxia ShiState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou P. R. China.ORCID https://orcid.org/0000-0002-5414-8049 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
This multicenter study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (ICI-Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first-line setting. We included patients with unfavorable CUP across four medical centers in China. Between January 2014 and December 2023, 117 patients were enrolled: 46 patients in the ICI-Chemo group and 71 patients in the Chemo group. After a median follow-up of 28.1 months, the ICI-Chemo group exhibited a significant improvement over the Chemo group in median PFS (9.10 months vs. 6.37 months; hazard ratio [HR] 0.46; 95% CI: 0.30-0.71;
Indexed as
cancer of unknown primarychemotherapyfirst‐line therapyoverall survivalPD‐1/PD‐L1 inhibitors
Identifiers
PMID40060196
PMCPMC11885889
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390